A pilot open label, single dose trial of fenobam in adults with fragile X syndrome

OBJECTIVE: A pilot open label, single dose trial of fenobam, an mGluR5 antagonist, was conducted to provide an initial evaluation of safety and pharmacokinetics in adult males and females with fragile X syndrome (FXS). METHODS: Twelve subjects, recruited from two fragile X clinics, received a single...

Descripción completa

Detalles Bibliográficos
Autores principales: Berry-Kravis, E, Hessl, D, Coffey, S, Hervey, C, Schneider, A, Yuhas, J, Hutchison, J, Snape, M, Tranfaglia, M, Nguyen, D V, Hagerman, R
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2009
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658751/
https://www.ncbi.nlm.nih.gov/pubmed/19126569
http://dx.doi.org/10.1136/jmg.2008.063701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658751/
https://www.ncbi.nlm.nih.gov/pubmed/19126569
http://dx.doi.org/10.1136/jmg.2008.063701

Ejemplares similares